IGHG3 and infection: Comparison of RV144 (ALVAC/AIDVAX) with VAX003 (AIDVAX alone) trials subsequently revealed that anti-V1V2 IgG3 correlated with a reduced infection risk in the RV144 trial and that the IgG3 responses were associated with high ADCC activities [8].